

Supplementary information to:

Review article:

**THE ASSOCIATION OF *ACE1*, *ACE2*, *TMPRSS2*, *IFITM3* AND *VDR*
POLYMORPHISMS WITH COVID-19 SEVERITY:
A SYSTEMATIC REVIEW AND META-ANALYSIS**


Zorana Dobrijević^{id}, Dragana Robajac^{id}, Nikola Gligorijević^{id}, Miloš Šunderić^{id},
Ana Penezić^{id}, Goran Miljuš^{id}, Olgica Nedić^{id}

University of Belgrade – Institute for the Application of Nuclear Energy (INEP), Belgrade,
Serbia


* **Corresponding author:** Zorana Dobrijević, Department for Metabolism, Institute for the
Application of Nuclear Energy (INEP), University of Belgrade, Belgrade, Serbia
Tel: +381 11 2618 666, E-mail: zorana.dobrijevic@inep.co.rs

<https://dx.doi.org/10.17179/excli2022-4976>


This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(<http://creativecommons.org/licenses/by/4.0/>).




Supplementary Figure 1: Meta-analysis of the association between rs1799752 in *ACE1* and COVID-19 severity: comparison severe vs. non-severe. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** II vs. DD; **F)** DI vs. DD. The results of the included studies presented as ORs, with 95 CI, and the overall effect with 95 % CI are shown in the forest plot. *P* values given are derived from heterogeneity tests.




Supplementary Figure 2: Meta-analysis of the association between rs12329760 in *TMPRSS2* and COVID-19 severity, after the exclusion of asymptomatic SARS-CoV-2 infected participants: comparison severe vs. non-severe. **A)** allelic model; **B)** recessive model; **C)** overdominant model; **D)** AA vs. GG; **E)** GA vs. GG. The results of the included studies presented as ORs, with 95 % CI, and the overall effect with 95 % CI are shown in the forest plot. *P* values given are derived from heterogeneity tests.




Supplementary Figure 3: Meta-analysis of the association between rs12252 in *IFITM3* and COVID-19 severity: comparison severe vs. moderate. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** CC vs. TT; **F)** TC vs. TT. The results of the included studies presented as ORs, with 95 % CI, and the overall effect with 95 % CI are shown in the forest plot. *P* values given are derived from heterogeneity tests.




Supplementary Figure 4: Meta-analysis of the association between rs2228570 in *VDR* and COVID-19 severity: comparison severe vs. non-severe. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** AA vs. GG; **F)** GA vs. GG. The results of the included studies presented as ORs, with 95 % CI, and the overall effect with 95 % CI are shown in the forest plot. *P* values given are derived from heterogeneity tests.



Supplementary Figure 5: Meta-analysis of the association between rs731236 in *VDR* and COVID-19 severity: comparison severe vs. non-severe. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** GG vs. AA; **F)** AG vs. AA. The results of the included studies presented as ORs, with 95 % CI, and the overall effect with 95 % CI are shown in the forest plot. *P* values given are derived from heterogeneity tests.



Supplementary Figure 6: Funnel plots for meta-analyses of the association between rs1799752 in *ACE1* and COVID-19 severity: comparison severe vs. moderate. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** II vs. DD; **F)** DI vs. DD. *P* values presented are derived from Egger's tests.



Supplementary Figure 7: Forest plots representing the results of sensitivity testing by leave-one-out meta-analysis of the association between rs1799752 in *ACE1* and COVID-19 severity: comparison severe vs. moderate. **A)** allelic model; **B)** dominant model; **C)** recessive model; **D)** overdominant model; **E)** II vs. DD; **F)** DI vs. DD. ORs with their 95 % CIs were used as risk estimates.

Supplementary Table 1: Newcastle-Ottawa scale quality assessment of the studies included in the qualitative synthesis

Authors*	Year	Selection				Comparability		Outcome		Score
		Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	
Gómez et al.	2020	*	*	*	*	*	*	*	*	8
Zhang et al.	2020	*	*	*	*	*	*	*	*	8
Abdollahzadeh et al.	2021	*	*	*	*		*	*	*	6
Akin et al.	2022	*	*	*	*	*	*	*	*	8
Aladag et al.	2021	*	*	*	*	*	*	*	*	8
Al-Anouti et al.	2021	*	*	*	*	**	*	*	*	9
Alghamdi et al.	2021	*	*	*	*	**	*	*	*	9
Apaydin et al.	2021	*	*	*	*	*	*	*	*	8
Cafiero et al.	2021	*	*	*	*	*	*	*	*	8
Cuesta-Llavona et al.	2021	*	*	*	*		*	*	*	7
Gómez et al.	2021	*	*	*	*	**	*	*	*	9
Gunal et al.	2021	*	*	*	*		*	*	*	7
Hubacek et al.	2021	*	*	*	*		*	*	*	7
Íñiguez et al.	2021	*	*	*	*	**	*	*	*	9
Karakaş Çelik et al.	2021	*	*	*	*		*	*	*	7
Kotur et al. (adults)	2021	*	*	*	*	**	*	*	*	9
Kouhpayeh et al.	2021	*	*	*	*	**	*	*	*	9
Mir et al.	2021	*	*	*	*		*	*	*	7
Möhlendick et al.	2021	*	*	*	*		*	*	*	7
Monticelli et al.	2021	*	*	*	*		*	*	*	6
Peralta et al.	2021	*	*	*	*		*	*	*	7
Ravikanth et al.	2021	*	*	*	*	**	*	*	*	9
Saad et al.	2021	*	*	*	*	**	*	*	*	9
Schönfelder et al.	2021a	*	*	*	*		*	*	*	7
Schönfelder et al.	2021b	*	*	*	*		*	*	*	7
Verma et al.	2021	*	*	*	*	**	*	*	*	9
Wulandari et al.	2021	*	*	*	*		*	*	*	7
Akbari et al.	2022	*	*	*	*	**	*	*	*	9
Akin et al.	2022	*	*	*	*	*	*	*	*	8
Wang et al.	2022	*	*	*	*		*	*	*	7

* References see main document